NZ596395A - Stable solid benzimidazole derivative preparation having optimized dissolution property - Google Patents
Stable solid benzimidazole derivative preparation having optimized dissolution propertyInfo
- Publication number
- NZ596395A NZ596395A NZ596395A NZ59639510A NZ596395A NZ 596395 A NZ596395 A NZ 596395A NZ 596395 A NZ596395 A NZ 596395A NZ 59639510 A NZ59639510 A NZ 59639510A NZ 596395 A NZ596395 A NZ 596395A
- Authority
- NZ
- New Zealand
- Prior art keywords
- benzimidazole
- biphenyl
- ethoxy
- methyl
- stable solid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- 238000004090 dissolution Methods 0.000 title abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 abstract 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 abstract 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 abstract 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 abstract 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 abstract 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 abstract 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000004386 Erythritol Substances 0.000 abstract 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 abstract 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229950007556 aranidipine Drugs 0.000 abstract 1
- 229950004646 azelnidipine Drugs 0.000 abstract 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 abstract 1
- 229960002992 barnidipine Drugs 0.000 abstract 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 abstract 1
- 229960004916 benidipine Drugs 0.000 abstract 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 abstract 1
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003020 cilnidipine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 dihydropyridine compound Chemical class 0.000 abstract 1
- 229950003102 efonidipine Drugs 0.000 abstract 1
- 235000019414 erythritol Nutrition 0.000 abstract 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract 1
- 229940009714 erythritol Drugs 0.000 abstract 1
- 229960003580 felodipine Drugs 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229960003963 manidipine Drugs 0.000 abstract 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001783 nicardipine Drugs 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- 229960005366 nilvadipine Drugs 0.000 abstract 1
- 229960000227 nisoldipine Drugs 0.000 abstract 1
- 229960005425 nitrendipine Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ABSTRACT - 596395 The disclosure relates to a solid preparation comprising (i) compound selected from the group consisting of 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, and 2-ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt thereof, (ii) a sugar alcohol selected from mannitol, sorbitol or erythritol, (iii) a dihydropyridine compound having calcium antagonistic activity, which is selected from azelnidipine, amlodipine, aranidipine, efonidipine, cilnidipine, nicardipine, nisoldipine, nitrendipine, nifedipine, nilvadipine, barnidipine, felodipine, benidipine, manidipine or a salt thereof. These solid preparations are stable and have an appropriately controlled dissolution rate of the active ingredient in the gastrointestinal tract.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009111381 | 2009-04-30 | ||
| JP2010068625 | 2010-03-24 | ||
| PCT/JP2010/057923 WO2010126168A2 (en) | 2009-04-30 | 2010-04-28 | Solid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596395A true NZ596395A (en) | 2013-06-28 |
Family
ID=43032637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596395A NZ596395A (en) | 2009-04-30 | 2010-04-28 | Stable solid benzimidazole derivative preparation having optimized dissolution property |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP2424501A2 (en) |
| JP (1) | JP5666471B2 (en) |
| KR (1) | KR101797776B1 (en) |
| CN (1) | CN102481248B (en) |
| AU (1) | AU2010242308A1 (en) |
| BR (1) | BRPI1014388A2 (en) |
| CA (1) | CA2760073A1 (en) |
| CL (1) | CL2011002662A1 (en) |
| CO (1) | CO6470841A2 (en) |
| CR (1) | CR20110581A (en) |
| DO (1) | DOP2011000329A (en) |
| EA (1) | EA201171329A1 (en) |
| EC (1) | ECSP11011494A (en) |
| GE (1) | GEP20135940B (en) |
| IL (1) | IL215962A0 (en) |
| MA (1) | MA33280B1 (en) |
| MX (1) | MX2011011011A (en) |
| MY (1) | MY158158A (en) |
| NZ (1) | NZ596395A (en) |
| PE (1) | PE20120315A1 (en) |
| SG (1) | SG175794A1 (en) |
| TW (1) | TWI438201B (en) |
| WO (1) | WO2010126168A2 (en) |
| ZA (1) | ZA201108375B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL236001B1 (en) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition, |
| KR101535586B1 (en) * | 2014-08-01 | 2015-07-09 | 에스케이케미칼주식회사 | Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban |
| KR101806004B1 (en) * | 2015-01-30 | 2017-12-08 | 씨제이헬스케어 주식회사 | A pharmaceutical composition comprising candesartan and amlodipine |
| CN106668016B (en) * | 2015-11-11 | 2020-06-23 | 江苏先声药业有限公司 | Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof |
| JP2017210435A (en) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | Method for producing irbesartan and amlodipine besylate-containing tablet |
| JP2019001782A (en) * | 2017-06-14 | 2019-01-10 | 東和薬品株式会社 | Bilayer tablet |
| JP7101464B2 (en) * | 2017-09-28 | 2022-07-15 | エルメッド株式会社 | A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same. |
| CN108210472A (en) * | 2017-12-15 | 2018-06-29 | 蚌埠丰原医药科技发展有限公司 | A kind of Cilnidipine solid dispersions tablet and preparation method thereof |
| CN108685925B (en) * | 2018-05-15 | 2019-12-06 | 徐州医科大学 | application of compound AB-38b in preparation of medicine for treating diabetic nephropathy |
| JP2020075869A (en) * | 2018-11-05 | 2020-05-21 | 日本ケミファ株式会社 | Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients |
| JP7206872B2 (en) * | 2018-12-07 | 2023-01-18 | ニプロ株式会社 | Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same |
| JP2020090471A (en) * | 2018-12-07 | 2020-06-11 | ニプロ株式会社 | Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same |
| JP7441105B2 (en) * | 2020-03-31 | 2024-02-29 | 日本ジェネリック株式会社 | Film-coated tablets containing azilsartan and amlodipine besilate |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2814513B2 (en) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | Pharmaceutical composition with improved dissolution |
| JP3057471B2 (en) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | Agent for preventing or treating angiotensin II-mediated diseases |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| WO2002074340A1 (en) * | 2001-03-16 | 2002-09-26 | Takeda Chemical Industries, Ltd. | Process for producing sustained release preparation |
| WO2003047573A1 (en) * | 2001-12-03 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
| JP4743684B2 (en) * | 2002-05-22 | 2011-08-10 | 塩野義製薬株式会社 | Method for improving dissolution of poorly water-soluble drugs |
| WO2004048363A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND USE |
| JP4769082B2 (en) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | Urea derivatives, their production and use |
| TWI396686B (en) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | Cyclic guanamine derivatives, as well as their products and usage |
| JP2006321726A (en) * | 2005-05-17 | 2006-11-30 | Sysmex Corp | Method for controlling elution property of tablet |
| WO2007001065A2 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Method for the preparation of a wet granulated drug product |
| CN101247832B (en) * | 2005-06-27 | 2011-12-28 | 第一三共株式会社 | Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker |
| DE102005031577A1 (en) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist |
| MX351987B (en) * | 2007-03-29 | 2017-11-03 | Daiichi Sankyo Co Ltd | Pharmaceutical composition. |
| UY32126A (en) * | 2008-09-25 | 2010-04-30 | Takeda Pharmaceutical | SOLID PHARMACEUTICAL COMPOSITION |
-
2010
- 2010-04-28 JP JP2011545129A patent/JP5666471B2/en active Active
- 2010-04-28 CA CA2760073A patent/CA2760073A1/en not_active Abandoned
- 2010-04-28 BR BRPI1014388A patent/BRPI1014388A2/en not_active IP Right Cessation
- 2010-04-28 NZ NZ596395A patent/NZ596395A/en not_active IP Right Cessation
- 2010-04-28 EP EP10719654A patent/EP2424501A2/en not_active Withdrawn
- 2010-04-28 MA MA34358A patent/MA33280B1/en unknown
- 2010-04-28 MY MYPI2011005206A patent/MY158158A/en unknown
- 2010-04-28 MX MX2011011011A patent/MX2011011011A/en not_active Application Discontinuation
- 2010-04-28 GE GEAP201012480A patent/GEP20135940B/en unknown
- 2010-04-28 CN CN2010800289702A patent/CN102481248B/en not_active Expired - Fee Related
- 2010-04-28 WO PCT/JP2010/057923 patent/WO2010126168A2/en not_active Ceased
- 2010-04-28 EA EA201171329A patent/EA201171329A1/en unknown
- 2010-04-28 PE PE2011001882A patent/PE20120315A1/en not_active Application Discontinuation
- 2010-04-28 SG SG2011078391A patent/SG175794A1/en unknown
- 2010-04-28 KR KR1020117027421A patent/KR101797776B1/en active Active
- 2010-04-28 TW TW099113442A patent/TWI438201B/en active
- 2010-04-28 AU AU2010242308A patent/AU2010242308A1/en not_active Abandoned
-
2011
- 2011-10-26 IL IL215962A patent/IL215962A0/en unknown
- 2011-10-26 CL CL2011002662A patent/CL2011002662A1/en unknown
- 2011-10-26 DO DO2011000329A patent/DOP2011000329A/en unknown
- 2011-11-08 CR CR20110581A patent/CR20110581A/en unknown
- 2011-11-15 ZA ZA2011/08375A patent/ZA201108375B/en unknown
- 2011-11-30 EC EC2011011494A patent/ECSP11011494A/en unknown
- 2011-11-30 CO CO11164599A patent/CO6470841A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11011494A (en) | 2011-12-30 |
| KR20120026060A (en) | 2012-03-16 |
| CN102481248B (en) | 2013-12-11 |
| BRPI1014388A2 (en) | 2016-04-05 |
| MA33280B1 (en) | 2012-05-02 |
| ZA201108375B (en) | 2013-01-30 |
| PE20120315A1 (en) | 2012-04-07 |
| WO2010126168A2 (en) | 2010-11-04 |
| JP2012525323A (en) | 2012-10-22 |
| CR20110581A (en) | 2012-01-19 |
| TW201041873A (en) | 2010-12-01 |
| AU2010242308A1 (en) | 2011-12-01 |
| EA201171329A1 (en) | 2012-05-30 |
| GEP20135940B (en) | 2013-10-10 |
| DOP2011000329A (en) | 2011-11-15 |
| TWI438201B (en) | 2014-05-21 |
| MY158158A (en) | 2016-09-15 |
| JP5666471B2 (en) | 2015-02-12 |
| CL2011002662A1 (en) | 2012-06-15 |
| CO6470841A2 (en) | 2012-06-29 |
| CN102481248A (en) | 2012-05-30 |
| IL215962A0 (en) | 2012-01-31 |
| MX2011011011A (en) | 2011-11-02 |
| EP2424501A2 (en) | 2012-03-07 |
| KR101797776B1 (en) | 2017-11-14 |
| WO2010126168A3 (en) | 2011-03-03 |
| SG175794A1 (en) | 2011-12-29 |
| CA2760073A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596395A (en) | Stable solid benzimidazole derivative preparation having optimized dissolution property | |
| CA2514921A1 (en) | Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension | |
| CA2613417A1 (en) | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker | |
| JP2012525323A5 (en) | ||
| RU2014111474A (en) | METHODS OF TREATMENT OF CARDIOVASCULAR DISORDERS | |
| MY160000A (en) | Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin ii antagonist and/or diuretic | |
| JP2010529205A5 (en) | ||
| WO2010100476A3 (en) | Improved process | |
| BR112013032122A2 (en) | modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide solubilized using organic acids | |
| NZ597317A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| IL188583A0 (en) | Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist | |
| CO6311067A2 (en) | PREPARATION OF TABLETS WITH DELAYED RELEASE CONTAINING POLYVINROL PIRROLIDONAS AND ACTIVE PRINCIPLE | |
| CL2011000625A1 (en) | Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation. | |
| AR061790A1 (en) | SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, FORMULATIONS OF IMMEDIATE RELEASE TABLETS OF A THROMBIN RECEIVER ANTAGONIST, AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| BRPI0509645A (en) | deferairox dispensable tablets | |
| ES2637024T3 (en) | Pharmaceutical composition for the treatment of inflammatory diseases mediated by MCP-1 | |
| JP6532984B2 (en) | Combination medication for the prevention or treatment of hypertension | |
| RU2012151051A (en) | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION | |
| CA3015964C (en) | Medicine for treating renal disease | |
| WO2008064338A3 (en) | Valsartan formulation for pulsatile delivery | |
| ATE462414T1 (en) | SOLID PREPARATION CONTAINING IRBESARTAN | |
| HRP20170267T1 (en) | COMBINATION (3S, 3S ') 4,4'-DISULPHANDIILBIS (3-AMINOBUTANE 1-SULPHONIC ACIDS) AND OTHER ANTI-HYPERTENSIVE AGENCY | |
| HK1259806A1 (en) | Medicine for treating renal disease | |
| TH118207A (en) | Pharmaceutical constituents of solids containing benzene immidazole | |
| RU2023129881A (en) | COMPOSITIONS FOR TREATMENT OF HYPERTENSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 APR 2017 BY CPA GLOBAL Effective date: 20140327 |
|
| LAPS | Patent lapsed |